Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.


Biomarker Discovery OMNI, Genentech Inc, South San Francisco, California, USA [Email] [Email]


To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally.


dmards (synthetic),early rheumatoid arthritis,inflammation,synovitis,

OUR Recent Articles